Classically, p53 tumor suppressor acts in transcription, apoptosis, and cell cycle arrest. Yet, 11 replication-mediated genomic instability is integral to oncogenesis, and p53 mutations promote 12 tumor progression and drug-resistance. By delineating human and murine separation-of-function 13 p53 alleles, we find that p53 null and gain-of-function (GOF) mutations exhibit defects in restart 14 of stalled or damaged DNA replication forks driving genomic instability independent of 15 transcription activation. By assaying protein-DNA fork interactions in single cells, we unveil a 16 p53-MLL3-enabled recruitment of MRE11 DNA replication restart nuclease. Importantly, p53 17 defects or depletion unexpectedly allow mutagenic RAD52 and POLq pathways to hijack stalled 18 forks, which we find reflected in p53 defective breast-cancer patient COSMIC mutational 19 signatures. These data uncover p53 as a keystone regulator of replication homeostasis within a 20 DNA restart network. Mechanistically, this has important implications for development of 21 2 resistance in cancer therapy. Combined, these results define an unexpected role for p53 22 suppression of replication genome instability. 23 
Introduction
One of the most prominent hallmarks of cancer is genomic instability (Hanahan and Weinberg, 28 2011). As such, many DNA damage response or repair genes that restore genome stability are 29 known tumor suppressors, including p53, the guardian of the genome (Kim et al., 2015) . In 30 breast cancers, p53 mutations are associated with more aggressive and triple negative breast 31 cancers (Turner et al., 2013) . Similar to high serous ovarian cancers, these aggressive cancers 32 respond to chemotherapy including platinum drugs and PARP inhibitors initially, but develop 33 resistance thereafter (Luvero et al., 2014; Wahba and El-Hadaad, 2015) . 34 First thought to be a proto-oncogene, the initial discovery of a gain-of-function (GOF) 35 p53 mutant allele (Lane and Crawford, 1979; Levine and Oren, 2009; Linzer and Levine, 1979) 36 masked the loss of wild-type (WT) p53 function. Despite early discrepancies, only a decade later 37 p53 was recognized as a tumor suppressor (Baker et al., 1989) . Loss of p53 function can occur 38 either by deletion or by mutation that otherwise may exhibit a GOF, typically enhancing 39 transcription functions. To date, the most consistent defect for both null and GOF p53 mutants in 40 cancers relates to p53's transcription factor function to promoting apoptosis and cell cycle arrest. 41 Genetic data of several separation-of-function p53 mutant mice suggest that there are 42 additional p53 functions that contribute to tumor progression, which are transcription , 2015) . p53 also has seemingly disparate cellular functions including during 48 metabolism and epigenetic control, i.e. through its interaction with MLL3/4 histone 49 methyltransferases (Pfister et al., 2015; Zhu et al., 2015) , although the contribution of these 50 functions to tumor suppression is not fully understood. 51 For cancer, a prominent p53 function is to maintain genomic stability upon DNA damage 52 as part of a damage response. Since DNA damage traditionally is most prominently considered 53 in the context of double-strand break (DSB) lesions, many studies focus on putative p53 54 functions in DSB repair. Next to error-free repair of DSBs by homologous recombination (HR) 55 involving BRCA1/2 and RAD51, DSBs may also be repaired by non-homologous end joining 56 (NHEJ), or through secondary and typically mutagenic pathways of single strand annealing Here we identify a critical role for p53 in balancing replication pathway homeostasis and 82 show p53 suppresses replication genomic instability independent of transcription activation. We 83 find p53 mutant alleles that separate transcription activation and replication restart functions and 84 reveal a direct correlation between p53 replication and tumor progression functions. Importantly, 85 we find mutagenic RAD52/POLq replication pathways increase for both GOF and p53 null 86 alleles in a transcription independent manner, consistent with mutation signatures that we 87 identify in p53 mutant breast cancers. Our results thus allow for an unexpected alternative 88 hypothesis for acquisition of resistance in breast cancer cells due to p53 loss: mutant p53 boosts 89 mutagenic RAD52/POLq pathways, which increase deletion and point mutations that can lead to 90 secondary resistance mutations. Figure 1A) , we assessed the number of stalled replication forks 105 after low-dose replication stalling ( Figure 1A) , as a test for defects in replication restart. We find 106 a doubling of stalled forks in CRISPR/CAS9-engineered p53-null human HAP-1 cells 107 compared to cells with wild-type (WT) p53 ( Figure 1B ; 35% stalled forks in p53 null 18% WT 108 p53 HAP-1). This suggests a prominent role for p53 in the resumption of DNA replication after 109 replication stress. 110 Increased fork stalling is classically compensated for by increased new origin firing, as 111 seen for CHK1 defects . Unexpectedly, 112 we find that increased fork stalling in p53 null cells is accompanied by a decrease, rather than an Figure 3A ). Specifically, we applied sensitive proximity ligation chemistry to 202 detect interactions between nascent, EdU labeled DNA and proteins within nanometer proximity. 203 The signal is specific as elimination of EdU results in no signals ( Figure 3A Saos-2 cells and U2OS cells, which are p53 WT sarcoma cells ( Figure 4B ). p53 null Saos-2 235 show an increase in RAD51 SIRF signals, which is repressed with expression of mutant p53 236 GOF R175H and R273H. Together, these results support no correlation between RAD51 237 recruitment to forks and fork instability in these cells, but instead suggest alternative causation 238 for the observed genomic instability in p53 mutant cells. , 2006) . We therefore tested whether increased 245 RAD52 recruitment is altered with p53 deletions. Using SIRF analysis, we find a marked 246 increase of RAD52 bound to stalled forks in p53-null cells ( Figure 4C ). As the signals were too 247 abundant to be individually counted, we used the mean fluorescence intensity (MFI) as a 248 quantitative readout ( Figure 4C , MFI of 494 in p53 null and 762 in p53 WT HAP-1 cells). 249 Notably, we see stronger RAD52 recruitment at low compared to high concentration of HU 250 (Figure 4 -figure supplement 1C) . The former condition is less favorable for DSB formation, 251 suggesting RAD52 recruitment to stalled forks is stronger than to bona fide DNA breaks. therefore tested if DNA POLq may contribute to mutagenic events at imbalanced stalled forks. 272 We find an increase of mutant p53 S47 association with POLq in unchallenged H1299 cells, 273 which is further enhanced with replication stalling ( Figure 5D To further test pathway imbalance specific to local stalled forks and dependent on p53 289 status, we performed SIRF against POLq in HAP-1 cells ( Figure 5D ). Consistently, we find 290 increased POLq recruitment to stalled forks in p53-null HAP-1 cells ( Figure 5D ). Similarly, 291 inactivation of MRE11 nuclease in WT HAP-1 cells causes a significantly increase in 292 recruitment of POLq to stalled forks. Together these data uncover p53-MRE11 repression of 293 mutagenic RAD52 and POLq processes at replication forks. . 339 We here identify a new p53 function in suppressing genome instability at replication 340 forks by promoting MLL3/MRE11-mediated replication pathway homeostasis. Importantly, this 341 activity, which we show is independent of p53 transcription activation roles, avoids mutagenic 342 RAD52/POLq pathways likely acting at reversed forks (Figure 7) . As replication mutations are 343 thought to be the strongest cancer mutation driver and genome instability is associated with 344 tumorigenesis, we propose that the here identified role of p53 as a replication homeostasis keeper 345 to avoid genome instability provides a feasible novel additional p53 tumor suppression function. 346 Moreover, the resulting understanding of p53-mediated genomic stability reconciles previous 347 reports on apoptosis and p53 transactivation-independent roles of p53 for tumor suppression 348 (Phang et al., 2015) . So far, the most consistent common defect to both GOF mutant p53 and p53 349 gene deletion is related to its transcription function in apoptosis and cell cycle arrest. These 360 We propose that upon activation by replication stress, p53 orchestrates balanced error-361 free replication restart and suppresses genome instability, which is caused by excessive usage of 362 mutagenic replication pathways when p53 is defective. Importantly, this model implies p53 363 promotes a replication homeostasis balance at forks for successful proliferation rather than a 364 strict pathway control. If replication stress exceeds a threshold for proper genome maintenance, 365 p53 may dissociate and, as a keystone replication stress regulator, induce cell death, including 366 but not exclusively through apoptosis, as an added safeguard to avoid cellular dysplasia. 367 368 p53 replication fork reactions and implied biological functions 369 We here find the African-decent tumor variant p53 P47S (S47) to be a separation of function 370 mutation defective in replication restart. p53 is phosphorylated by ATM at S46, which is 371 decreased in p53 S47 (Jennis et al., 2016) . Intriguingly, at the adjacent residues D48/D49, p53 372 can directly interact with single-strand binding protein RPA (Romanova et al., 2004) , which is 373 implicated in replication fork remodeling (Neelsen and Lopes, 2015) . Specifically, RPA 374 interaction mutations deregulate recombination reactions without affecting transactivation 375 reactions (Romanova et al., 2004) . By proximity of these residues and phenotypical 376 commonalities, we suggest that p53 P47S (S47) may also affect RPA interactions. By extension, 377 we propose that ATM phosphorylation of WT p53 may regulate such p53-RPA interactions for 378 the purpose of fork remodeling, as a controlled process for restart balancing. Notably, we find ). We therefore propose that p53 could feasibly be a vital player in the Fanconi Anemia 385 pathway through its replication function, and it will be exciting to decipher this feasible 386 relationship. 387 We establish here that at forks, p53 controls MRE11, a nuclease known to promote restart 
